Tricol Biomedical

Tricol Biomedical is a private, commercial-stage medical device company focused on hemostasis and wound care. Its core technology is a proprietary chitosan derivative called Chito+, which provides a polycationic charge to rapidly control bleeding. The company markets a portfolio of products across three segments: Trauma Management, Procedural Care, and Consumer Care, stemming from its original battlefield collaboration with the U.S. Army. Tricol operates a fully integrated model, from R&D to commercialization, and partners with other device companies.

Proprietary chitosan derivative (Chito+) with a strong polycationic charge that electrostatically binds to blood cells and tissue to rapidly control bleeding, independent of the body's coagulation pathway.

Tricol competes in the crowded hemostat market against large players like Baxter, Johnson & Johnson, and Teleflex, which offer products based on gelatin, collagen, thrombin, and kaolin. Its differentiation lies in the unique electrostatic mechanism of its proprietary chitosan, its battlefield heritage, and its focus on a fully integrated platform across multiple care settings.